1. Market Research
  2. > Hepatitis – Pipeline Review, H1 2013

Hepatitis – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 527 pages

Hepatitis – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Hepatitis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. Hepatitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatitis.
- A review of the Hepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hepatitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hepatitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hepatitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Hepatitis - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
Introduction 9
Hepatitis Overview 10
Therapeutics Development 11
Hepatitis Therapeutics under Development by Companies 13
Hepatitis Therapeutics under Investigation by Universities/Institutes 27
Late Stage Products 30
Mid Clinical Stage Products 31
Early Clinical Stage Products 32
Discovery and Pre-Clinical Stage Products 33
Hepatitis Therapeutics - Products under Development by Companies 34
Hepatitis Therapeutics - Products under Investigation by Universities/Institutes 57
Companies Involved in Hepatitis Therapeutics Development 59
Hepatitis - Therapeutics Assessment 214
Drug Profiles 222
Hepatitis Therapeutics - Drug Profile Updates 402
Hepatitis Therapeutics - Discontinued Products 478
Hepatitis Therapeutics - Dormant Products 485
Hepatitis - Product Development Milestones 503
Appendix 513

List of Tables

Number of Products Under Development for Hepatitis, H1 2013 24
Products under Development for Hepatitis - Comparative Analysis, H1 2013 25
Number of Products under Development by Companies, H1 2013 27
Number of Products under Development by Companies, H1 2013 (Contd..1) 28
Number of Products under Development by Companies, H1 2013 (Contd..2) 29
Number of Products under Development by Companies, H1 2013 (Contd..3) 30
Number of Products under Development by Companies, H1 2013 (Contd..4) 31
Number of Products under Development by Companies, H1 2013 (Contd..5) 32
Number of Products under Development by Companies, H1 2013 (Contd..6) 33
Number of Products under Development by Companies, H1 2013 (Contd..7) 34
Number of Products under Development by Companies, H1 2013 (Contd..8) 35
Number of Products under Development by Companies, H1 2013 (Contd..9) 36
Number of Products under Development by Companies, H1 2013 (Contd..10) 37
Number of Products under Development by Companies, H1 2013 (Contd..11) 38
Number of Products under Development by Companies, H1 2013 (Contd..12) 39
Number of Products under Investigation by Universities/Institutes, H1 2013 41
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 42
Comparative Analysis by Late Stage Development, H1 2013 43
Comparative Analysis by Mid Clinical Stage Development, H1 2013 44
Comparative Analysis by Early Clinical Stage Development, H1 2013 45
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 46
Products under Development by Companies, H1 2013 47
Products under Development by Companies, H1 2013 (Contd..1) 48
Products under Development by Companies, H1 2013 (Contd..2) 49
Products under Development by Companies, H1 2013 (Contd..3) 50
Products under Development by Companies, H1 2013 (Contd..4) 51
Products under Development by Companies, H1 2013 (Contd..5) 52
Products under Development by Companies, H1 2013 (Contd..6) 53
Products under Development by Companies, H1 2013 (Contd..7) 54
Products under Development by Companies, H1 2013 (Contd..8) 55
Products under Development by Companies, H1 2013 (Contd..9) 56
Products under Development by Companies, H1 2013 (Contd..10) 57
Products under Development by Companies, H1 2013 (Contd..11) 58
Products under Development by Companies, H1 2013 (Contd..12) 59
Products under Development by Companies, H1 2013 (Contd..13) 60
Products under Development by Companies, H1 2013 (Contd..14) 61
Products under Development by Companies, H1 2013 (Contd..15) 62
Products under Development by Companies, H1 2013 (Contd..16) 63
Products under Development by Companies, H1 2013 (Contd..17) 64
Products under Development by Companies, H1 2013 (Contd..18) 65
Products under Development by Companies, H1 2013 (Contd..19) 66
Products under Development by Companies, H1 2013 (Contd..20) 67
Products under Development by Companies, H1 2013 (Contd..21) 68
Products under Development by Companies, H1 2013 (Contd..22) 69
Products under Investigation by Universities/Institutes, H1 2013 70
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 71
Bristol-Myers Squibb Company, H1 2013 72
Johnson and Johnson, H1 2013 73
Boehringer Ingelheim GmbH, H1 2013 74
F. Hoffmann-La Roche Ltd., H1 2013 75
United Therapeutics Corporation, H1 2013 76
Medgenics Inc., H1 2013 77
Valeant Pharmaceuticals International, H1 2013 78
GlaxoSmithKline plc, H1 2013 79
Tekmira Pharmaceuticals Corp., H1 2013 80
Inovio Biomedical Corporation, H1 2013 81
Idenix Pharmaceuticals, Inc., H1 2013 82
Gilead Sciences, Inc., H1 2013 83
Merck and Co., Inc., H1 2013 84
Lentigen Corporation, H1 2013 85
BioLineRx, Ltd., H1 2013 86
Celltrion, Inc., H1 2013 87
Biological E. Limited, H1 2013 88
Biotron Limited, H1 2013 89
Novartis AG, H1 2013 90
Isotechnika Pharma Inc., H1 2013 91
Achillion Pharmaceuticals, Inc., H1 2013 92
Chugai Pharmaceutical Co. Ltd, H1 2013 93
InterMune, Inc., H1 2013 94
Ono Pharmaceutical Co., Ltd., H1 2013 95
Pfizer Inc., H1 2013 96
SuperGen, Inc., H1 2013 97
Toyama Chemical Co. Ltd, H1 2013 98
Vertex Pharmaceuticals Incorporated, H1 2013 99
Genmab A/S, H1 2013 100
Santaris Pharma A/S, H1 2013 101
Aduro BioTech, H1 2013 102
Alfacell Corporation, H1 2013 103
CEL-SCI Corporation, H1 2013 104
Crucell N.V., H1 2013 105
Celgene Corporation, H1 2013 106
Zosano Pharma, Inc., H1 2013 107
4SC AG, H1 2013 108
EpiCept Corporation, H1 2013 109
Hemispherx Biopharma, Inc., H1 2013 110
Agenix Limited, H1 2013 111
Immtech Pharmaceuticals, Inc., H1 2013 112
Can-Fite BioPharma Ltd., H1 2013 113
Arrowhead Research Corporation, H1 2013 114
Ligand Pharmaceuticals Incorporated, H1 2013 115
Medivir AB, H1 2013 116
Benitec Ltd., H1 2013 117
BioDiem Ltd, H1 2013 118
Novelos Therapeutics, Inc., H1 2013 119
Peregrine Pharmaceuticals, Inc., H1 2013 120
CytoGenix, Inc., H1 2013 121
Amarillo Biosciences, Inc., H1 2013 122
Flamel Technologies S.A., H1 2013 123
Dynavax Technologies Corporation, H1 2013 124
Transgene SA, H1 2013 125
Lipoxen PLC, H1 2013 126
Miraca Holdings Inc., H1 2013 127
Green Cross Corporation, H1 2013 128
Hanall Pharmaceutical Co., Ltd., H1 2013 129
MOLOGEN AG, H1 2013 130
LG Life Sciences, Ltd, H1 2013 131
Theravance, Inc., H1 2013 132
LTT Bio-Pharma Co., Ltd., H1 2013 133
Uni-Bio Science Group Ltd., H1 2013 134
Panacea Biotec Limited, H1 2013 135
Summit Corporation plc, H1 2013 136
Phynova Group Ltd, H1 2013 137
Tripep AB, H1 2013 138
Digna Biotech, S.L., H1 2013 139
Debiopharm Group, H1 2013 140
Immune Network Research Ltd., H1 2013 141
Functional Genetics, Inc., H1 2013 142
StemCells, Inc., H1 2013 143
Colby Pharmaceutical Company, H1 2013 144
SCYNEXIS, Inc., H1 2013 145
China National Biotec Group, H1 2013 146
Nutri Pharma ASA, H1 2013 147
Mucosis B.V., H1 2013 148
ImmunoBiology Limited, H1 2013 149
Cytheris SA, H1 2013 150
Altor BioScience Corporation, H1 2013 151
Anacor Pharmaceuticals, Inc., H1 2013 152
Eiger BioPharmaceuticals, Inc., H1 2013 153
Ambrx, Inc., H1 2013 154
Mondobiotech Holding AG, H1 2013 155
AiCuris GmbH and Co. KG, H1 2013 156
Okairos, H1 2013 157
GeneScience Pharmaceuticals Co., Ltd., H1 2013 158
PTC Therapeutics, Inc., H1 2013 159
Conatus Pharmaceuticals Inc., H1 2013 160
Kineta, Inc., H1 2013 161
Presidio Pharmaceuticals, Inc., H1 2013 162
Romark Laboratories, L.C., H1 2013 163
Chimerix, Inc., H1 2013 164
Phage Biotechnology Corporation, H1 2013 165
Intarcia Therapeutics, Inc., H1 2013 166
REPLICor Inc., H1 2013 167
Biotica Technology Ltd, H1 2013 168
Immune Targeting Systems (ITS) Ltd., H1 2013 169
VLST Corporation, Inc., H1 2013 170
Virobay Inc., H1 2013 171
Wittycell S.A.S., H1 2013 172
Concert Pharmaceuticals, Inc., H1 2013 173
Genexine Co., Ltd., H1 2013 174
Immunotope, Inc., H1 2013 175
Implicit Bioscience Limited, H1 2013 176
Microbiotix, Inc., H1 2013 177
NanoBio Corporation, H1 2013 178
Bolder Biotechnology, Inc., H1 2013 179
ImmunoVaccine Technologies Inc., H1 2013 180
Oncolys BioPharma Inc., H1 2013 181
Globeimmune, Inc., H1 2013 182
Immunocore Limited., H1 2013 183
Enanta Pharmaceuticals, Inc., H1 2013 184
Canopus BioPharma Incorporated, H1 2013 185
ChemoCentryx, Inc., H1 2013 186
PepTcell Limited, H1 2013 187
TVAX Biomedical, LLC, H1 2013 188
Quintessence Biosciences, Inc., H1 2013 189
Epiphany Biosciences, Inc., H1 2013 190
Alios BioPharma, Inc., H1 2013 191
Vaxart, Inc., H1 2013 192
TaiGen Biotechnology Co., Ltd., H1 2013 193
Variation Biotechnologies, Inc., H1 2013 194
IRX Therapeutics, Inc., H1 2013 195
PharmaEssentia Corporation, H1 2013 196
NasVax Ltd., H1 2013 197
Johnson and Johnson Pharmaceutical Research and Development, L.L.C., H1 2013 198
Immunotech Laboratories, Inc., H1 2013 199
iQur Ltd., H1 2013 200
Regulus Therapeutics Inc., H1 2013 201
Tibotec Pharmaceuticals Ltd., H1 2013 202
AIMM Therapeutics B.V., H1 2013 203
China Biologic Products, Inc., H1 2013 204
Ramot at Tel Aviv University Ltd., H1 2013 205
3-V Biosciences, Inc., H1 2013 206
Ascenion GmbH, H1 2013 207
Gaia BioPharma Limited, H1 2013 208
DiscoveryBiomed, Inc., H1 2013 209
Ascendis Pharma A/S, H1 2013 210
ViiV Healthcare, H1 2013 211
ViroLogik GmbH, H1 2013 212
Vakzine Projekt Management GmbH, H1 2013 213
BandC Biopharm, H1 2013 214
SelectX Pharmaceuticals, Inc., H1 2013 215
RFS Pharma, LLC, H1 2013 216
Prosetta Corporation, H1 2013 217
Therapure Biopharma Inc., H1 2013 218
Vaxine Pty Ltd, H1 2013 219
DEKK-TEC, Inc., H1 2013 220
iTherX Pharmaceuticals Inc., H1 2013 221
VLP Biotech, Inc., H1 2013 222
ImQuest Life Sciences, H1 2013 223
AUS Bio Limited, H1 2013 224
AltraVax Inc., H1 2013 225

List of Figures

Number of Products under Development for Hepatitis, H1 2013 24
Products under Development for Hepatitis - Comparative Analysis, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Investigation by Universities/Institutes, H1 2013 40
Late Stage Products, H1 2013 43
Mid Clinical Stage Products, H1 2013 44
Early Clinical Stage Products, H1 2013 45
Discovery and Pre-Clinical Stage Products, H1 2013 46
Assessment by Monotherapy Products, H1 2013 227
Assessment by Combination Products, H1 2013 228
Assessment by Route of Administration, H1 2013 229
Assessment by Stage and Route of Administration, H1 2013 230
Assessment by Molecule Type, H1 2013 232
Assessment by Stage and Molecule Type, H1 2013 233

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.